Eye Health News and Research

Latest Eye Health News and Research

New research at Tel Aviv University may lay groundwork for retinal implants in people

Television's Six Million Dollar Man foresaw a future when man and machine would become one. New research at Tel Aviv University is making this futuristic "vision" of bionics a reality.

23 Mar 2010

You and your baby may need vitamin D supplementation says research

This report appeared in the respected Journal Pediatrics this week. There has been growing awareness regarding deficiency of Vitamin D in children and adults. This vitamin is important for healthy bones, immunity and other bodily processes. In children inadequacy of this vitamin in diet may lead to bone damage, rickets, repeated infections and heart disease in later life.

23 Mar 2010

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Can-Fite BioPharma Ltd, a biopharmaceutical company, traded on the TASE and developing anti- inflammatory and anti-cancer drugs, announced today the filing of a patent application, in conjunction with the United Stated National Institutes of Health (NIH), for the treatment of Uveitis with its A3 adenosine receptor ligands.

23 Mar 2010

BCBSGA, OneSight bring regional clinic to Georgia to provide free vision care for school children

Blue Cross and Blue Shield of Georgia and OneSight®, a Luxottica Group Foundation have teamed to bring a regional clinic to Georgia from today, Monday, March 22, through Friday, March 26. Clayton County, Henry County and Spalding County Schools pre-selected approximately 600 students from kindergarten through high school based on their financial and vision needs to receive free vision care, including full vision exams and new eyewear.

23 Mar 2010

PanGenex finalizes partnership agreement with That’s Us Technologies

PanGenex Corporation a global manufacturer and distributor of nutraceutical and dietary supplement products, announced today that it has finalized a partnership agreement with That’s Us Technologies, Inc. (www.thatsus.com) a marketing company whose exclusive focus is internet marketing.

22 Mar 2010

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced the pending commercial launch of 13 new SFDA approved products over the next few quarters.

22 Mar 2010

Genetic study may help develop potential treatment strategies for stiff skin syndrome

By studying the genetics of a rare inherited disorder called stiff skin syndrome, researchers at the Johns Hopkins University School of Medicine have learned more about scleroderma, a condition affecting about one in 5,000 people that leads to hardening of the skin as well as other debilitating and often life-threatening problems.

20 Mar 2010

Prevent Blindness America, Real Kids Shades partner to promote children's eye protection

In an effort to educate parents about the need to protect children's eye health, Prevent Blindness America, the nation's leading volunteer eye health and safety organization, and Real Kids Shades a leading manufacturer of quality eyewear for infants and children, are teaming up to ensure that 5 million children have healthy eyes for healthy futures. The joint effort supports "Star Pupils," a national program of Prevent Blindness America designed to arm parents with the information they need to help their children achieve a lifetime of healthy vision.

19 Mar 2010

OXiGENE reports audited financial statements for fiscal year ended December 31, 2009

OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that the audit report from its independent registered public accounting firm on its financial statements for the fiscal year ended December 31, 2009, included in the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 16, 2010, contains an explanatory paragraph regarding the Company's ability to continue as a going concern.

19 Mar 2010

Studies reveal increased polyp detection rates with TER during colonoscopy

Two new studies show an increase in polyp detection rates using the Third Eye Retroscope (TER), a retrograde viewing device, during colonoscopy. The first study found that TER added to standard colonoscopy detected 13.2 percent more polyps than colonoscopy alone, including 11 percent additional adenomas (precancerous polyps). A second study examined endoscopist experience using TER and its impact on polyp detection rates, concluding that polyp detection rates improved significantly with TER.

19 Mar 2010

Bausch + Lomb ReNu MultiPlus multi-purpose solution named "Best Eye Care Product of the Year - Asia"

Bausch + Lomb ReNu MultiPlus(R) multi-purpose solution has been named "Best Eye Care Product of the Year - Asia" for its revolutionary bottle design at this year's A.S. Watson Global Suppliers Awards. Held in Hong Kong on 4 March 2010, the awards recognize international brands for outstanding performance in bringing innovation, differentiation and excitement to the consumer experience.

19 Mar 2010

Researchers use optogenetics technology to troubleshoot neural circuits

Recently, brain researchers have gained a powerful new way to troubleshoot neural circuits associated with depression, Parkinson's disease and other conditions in small animals such as rats. They use an optogenetics technology, invented at Stanford University, that precisely turns select brain cells on or off with flashes of light. Although useful, the optogenetics tool set has been limited.

19 Mar 2010

Overall mortality rates at Bay Medical Center in Panama City drop 1.3 points

Overall mortality rates from the end of 2007 to the beginning of 2010 at Bay Medical Center in Panama City, Florida have dropped from 3.4 to 2.1. A 1.3-point drop represents a huge reduction for any hospital and translates into lives saved.

19 Mar 2010

FDA approves Somaxon Pharmaceuticals' Silenor for treatment of insomnia

Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.

19 Mar 2010

Stiff skin syndrome cause found

18 Mar 2010

ISCO commences second phase of testing RPE derived from parthenogenetic stem cells

International Stem Cell Corporation, announced today that ISCO's Research and Therapeutic Development Group, together with a group of scientists from the University of California, Irvine (UCI), is starting a second phase of essential pre-clinical experiments to test retinal pigment epithelium derived from parthenogenetic stem cells. Follow on pre-clinical experiments will be conducted to rescue vision in disease models.

18 Mar 2010

Manitoba government: AMD drug Lucentis will be funded through centralized vision program

Manitobans with wet age-related macular degeneration (AMD) received a dose of good news. The Manitoba government announced that Lucentis (ranibizumab injection) will soon be funded through a centralized vision program, effective June 1, 2010.

18 Mar 2010

Academic Inventors’ Bill of Rights unveiled in poster presentation at AUTM Annual Meeting

As technology transfer managers from around the country prepare today to debate the role of academic researchers in commercializing their own inventions, two experts – one from each side of the aisle – have come together to propose an Academic Inventors’ Bill of Rights.

18 Mar 2010

Scientific revelations discovered during Retina Implant’s first human clinical trial

Retina Implant, AG, a leading developer of subretinal implants for the visually impaired, today announced scientific revelations discovered during the company’s first human clinical trial. The results achieved in the 11 patients that were involved in the trial exceeded the company’s expectations for their first trial.

18 Mar 2010

ForSight Labs licenses non-core ophthalmology technology from SurModics

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it has entered into an agreement with ForSight Labs, LLC to license certain non-core ophthalmology technology. The technology licensed in this agreement does not include the Company’s I-vation™ drug delivery technology. While the license agreement contains an up-front license fee, milestone payments and royalties, specific terms of the agreement were not disclosed.

18 Mar 2010

Eye Health News and Research

Latest Eye Health News and Research

New research at Tel Aviv University may lay groundwork for retinal implants in people

You and your baby may need vitamin D supplementation says research

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

BCBSGA, OneSight bring regional clinic to Georgia to provide free vision care for school children

PanGenex finalizes partnership agreement with That’s Us Technologies

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

Genetic study may help develop potential treatment strategies for stiff skin syndrome

Prevent Blindness America, Real Kids Shades partner to promote children's eye protection

OXiGENE reports audited financial statements for fiscal year ended December 31, 2009

Studies reveal increased polyp detection rates with TER during colonoscopy

Bausch + Lomb ReNu MultiPlus multi-purpose solution named "Best Eye Care Product of the Year - Asia"

Researchers use optogenetics technology to troubleshoot neural circuits

Overall mortality rates at Bay Medical Center in Panama City drop 1.3 points

FDA approves Somaxon Pharmaceuticals' Silenor for treatment of insomnia

Stiff skin syndrome cause found

ISCO commences second phase of testing RPE derived from parthenogenetic stem cells

Manitoba government: AMD drug Lucentis will be funded through centralized vision program

Academic Inventors’ Bill of Rights unveiled in poster presentation at AUTM Annual Meeting

Scientific revelations discovered during Retina Implant’s first human clinical trial

ForSight Labs licenses non-core ophthalmology technology from SurModics

Genetics & Genomics - Second Edition eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Eye Health News and Research

Latest Eye Health News and Research

Genetics & Genomics - Second Edition eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in